Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · IEX Real-Time Price · USD
1.500
-0.020 (-1.32%)
At close: Jul 19, 2024, 4:30 PM
1.420
-0.080 (-5.33%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $10.82 million as of July 22, 2024. Its market cap has decreased by -24.83% in one year.
Market Cap
10.82M
Enterprise Value
1.56M
1-Year Change
-24.83%
Ranking
Category
Stock Price
$1.50
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has decreased from $100.46M to $10.82M, a decrease of -89.22%. That is a compound annual growth rate of -46.40%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 19, 2024 | 9.70M | 24.36% |
| Dec 29, 2023 | 7.80M | -38.10% |
| Dec 30, 2022 | 12.60M | -65.95% |
| Dec 31, 2021 | 37.00M | -44.19% |
| Dec 31, 2020 | 66.30M | -34.00% |
View and export this data all the way back to 2020.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Cardio Diagnostics Holdings | 11.80M |
| Traws Pharma | 11.39M |
| Eterna Therapeutics | 11.36M |
| Calidi Biotherapeutics | 11.36M |
| MIRA Pharmaceuticals | 11.32M |
| BioRestorative Therapies | 11.17M |
| Dominari Holdings | 10.98M |
| Aptose Biosciences | 10.96M |